Render Target: STATIC
Render Timestamp: 2024-12-26T11:34:05.558Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:58:48.916
Product last modified at: 2024-12-17T18:58:56.206Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

NOVA1 (E9E6U) Rabbit mAb #65350

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 58
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    NOVA1 (E9E6U) Rabbit mAb recognizes endogenous levels of total NOVA1 protein. This antibody does not cross-react with NOVA2 protein. This antibody detects an 85 kDa band of unknown origin.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala36 of human NOVA1 protein.

    Background

    Neuro-oncological ventral antigen (NOVA) 1 and 2 are neuronal RNA-binding proteins (RBPs) that bind YCAY motifs to regulate alternative splicing (1-3). Both proteins have been shown to be targets in paraneoplastic opsoclonus myoclonus ataxia, a neuronal autoimmune disease (1,3). NOVA proteins rely on their KH3 domain to bind RNA and are reciprocally expressed in various parts of the brain (4). NOVA1 has been shown to be essential for neuronal viability, as it controls alternative splicing in GlyRalpha2 and GABA(A) receptor pre-mRNAs (5). NOVA1 is also capable of auto-regulation as it binds to its own exon 4, which contains a phosphorylated protein domain (6). NOVA1/2 double knockout mice are paralyzed due to lack of alternatively spliced agrin Z(+), which helps synapse formation at neuromuscular junctions (7). NOVA2 has been shown to regulate circular RNA biogenesis in the developing brain (8). NOVA1 has been shown to be highly expressed in many different cancer types, and can promote epithelial-mesenchymal transition by binding β-catenin mRNA (9,10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.